Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.

Y. Tong,M. Torrent,A. Florjancic,K. Bromberg,F. G. Buchanan,D. Ferguson,Eric F. Johnson,Loren M. Lasko,D. Maag,Philip J. Merta,A. Olson,Donald J. Osterling,N. Soni,A. Shoemaker,T. Penning

DOI: https://doi.org/10.1021/ml5002745

2015-01-08

ACS Medicinal Chemistry Letters

Abstract:Aided by molecular modeling, compounds with a pyrimidine-based tricyclic scaffold were designed and confirmed to inhibit Wee1 kinase. Structure-activity studies identified key pharmacophores at the aminoaryl and halo-benzene regions responsible for binding affinity with sub-nM K i values. The potent inhibitors demonstrated sub-μM activities in both functional and mechanism-based cellular assays and also possessed desirable pharmacokinetic profiles. The lead molecule, 31, showed oral efficacy in potentiating the antiproliferative activity of irinotecan, a cytotoxic agent, in a NCI-H1299 mouse xenograft model.